Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emricasan - Conatus Pharmaceuticals

Drug Profile

Emricasan - Conatus Pharmaceuticals

Alternative Names: IDN-6556; PF-03491390; PF-3,491,390; VAY 785

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idun Pharmaceuticals
  • Developer Conatus Pharmaceuticals
  • Class Amides; Aniline compounds; Antifibrotics; Antihyperglycaemics; Antihypertensives; Fluorobenzenes; Hepatoprotectants; Pentanoic acids; Phenyl ethers; Small molecules
  • Mechanism of Action Apoptosis inhibitors; Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatic fibrosis; Non-alcoholic fatty liver disease; Portal hypertension
  • Phase I/II Type 1 diabetes mellitus
  • Suspended Alcoholic hepatitis; Liver failure
  • No development reported Liver disorders
  • Discontinued Non-alcoholic steatohepatitis; Septic shock

Most Recent Events

  • 28 Jan 2020 Emricasan is still in phase II trials for Non-alcoholic steatohepatitis in Germany (Conatus Pharmaceuticals website - January 2020)
  • 28 Jan 2020 Emricasan is still in phase II trials for Portal hypertension in Germany and Spain (Conatus Pharmaceuticals website - January 2020)
  • 08 Nov 2019 Efficacy and adverse events data from the phase IIb ENCORE-NF trial in Non-alcoholic steatohepatitis cirrhosis presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top